Novel Coronavirus

Algoma Public Health

Appointment Booking Eligibility

  • Facebook
  • Email

 

Safe and effective vaccines will help protect us against COVID-19

 

Follow along with our COVID-19 Immunization Tracker as we provide regular up-to-date data on Algoma's COVID-19 vaccination rollout.

 

If you have questions specifically related to the vaccine itself, you can call Ontario’s Vaccine Information phone line1-888-999-6488

 

All Out of Province vaccines must be reported to Algoma Public Health and entered into the provincial system prior to booking an appointment for the bivalent booster dose.

 

Note: As of January, 2023, all COVID-19 immunization clinics across the Algoma District will be able to immunize eligible individuals aged 6 months and older.


 

Eligibility 


Use the table below to see which dose you may need next. Find your age to see the doses you are eligible to receive.

 

General Population Recommendations
Age Recommended Intervals

6 months to 4 years

 

*There is currently no vaccine preferred product for children 6 months to 4 years of age. Children within this age span may receive either a monovalent Pfizer (3 dose primary series) or monovalent Moderna (2 dose primary series).

Primary Series*

Pfizer-BioNTech (3mcg)

  • 2nd dose, 56 days after 1st dose
  • 3rd dose, 56 days after 2nd dose

 

Or*

 

Moderna (25 mcg)

  • 2nd dose, 56 days after 1st dose

 

Booster Doses - Not eligible

5 years and older

 

** Preferential recommendation for the use of Pfizer-BioNTech COVID-19 vaccine for individuals 5-29 years of age if receiving a primary series dose, or 5-17 years of age if receiving a booster dose. This is due to an increase in myocarditis/pericarditis following vaccination with Moderna in adolescents and young adults.

Primary Series

  • 2nd dose, 56 days after 1st dose

 

Booster Doses

  • 6 months (168 days) after last dose
Immunocompromised Recommendations

6 months to 4 years

 

Preferentially recommendation for the use of Moderna Spikevax primary series (25 mcg). If Moderna (25 mcg) is not readily available, a four-dose primary series of Pfizer-BioNTech (3 mcg) may be offered. This recommendation is due to feasibility in completion of the primary series, not due to any observed safety differences.

Primary Series

Pfizer-BioNTech (3mcg)

  • 2nd dose, 56 days after 1st dose
  • 3rd dose, 56 days after 2nd dose
  • 4th dose, 56 days after 3rd dose

 

Or*

 

Moderna (25 mcg)

  • 2nd dose, 56 days after 1st dose
  • 3rd dose, 56 days after 2nd dose

 

Booster Doses - Not eligible

5 years and older

Primary Series

  • 2nd dose, 56 days after 1st dose
  • 3rd dose, 56 days after 2nd dose

 

Booster Doses

  • 6 months (168 days) after last dose

 

 

Booster Doses Strengthen Protection against COVID-19

 

All individuals 5 and older are eligible and recommended to receive a bivalent booster dose 6 months after their previous dose in order to stay up to date with their COVID-19 vaccines.

 

Protection after a primary COVID-19 vaccine series (2 doses) decreases over time, especially against the Omicron variant of concern. COVID-19 vaccine booster doses help to increase protection against symptomatic infection and severe outcomes at the individual level and help to reduce transmission at the population level.

 

If eligible, it is recommended that a bivalent COVID-19 vaccine be administered as your next dose. If the bivalent COVID-19 vaccine is not readily available, an original COVID-19 vaccine should be offered to ensure timely protection.

Acknowledgement